Publications by authors named "Cyrille C Thinnes"

Computational modelling of microbiome metabolism has proved instrumental to catalyse our understanding of diet-host-microbiome-disease interactions through the interrogation of mechanistic, strain- and molecule-resolved metabolic models. We present APOLLO, a resource of 247,092 human microbial genome-scale metabolic reconstructions spanning 19 phyla and accounting for microbial genomes from 34 countries, all age groups, and five body sites. We explored the metabolic potential of the reconstructed strains and developed a machine learning classifier able to predict with high accuracy the taxonomic strain assignments.

View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on the inhibition of JMJD6, an oxygenase linked to cancer, using 2-oxoglutarate mimics and competitors, including existing drugs and drug candidates.
  • Researchers utilized NMR to observe how inhibitors bind to JMJD6 and mass spectrometry to track its lysine hydroxylation activity.
  • Findings indicate that certain prolyl hydroxylase inhibitors also affect JMJD6, which could aid in creating selective inhibitors for oxygenases like JMJD6 in cancer therapy.
View Article and Find Full Text PDF

Background: Parkinson's disease (PD) is a systemic disease clinically defined by the degeneration of dopaminergic neurons in the brain. While alterations in the gut microbiome composition have been reported in PD, their functional consequences remain unclear. Herein, we addressed this question by an analysis of stool samples from the Luxembourg Parkinson's Study (n = 147 typical PD cases, n = 162 controls).

View Article and Find Full Text PDF

Parkinson's disease (PD) exhibits systemic effects on the human metabolism, with emerging roles for the gut microbiome. Here, we integrate longitudinal metabolome data from 30 drug-naive, de novo PD patients and 30 matched controls with constraint-based modeling of gut microbial communities derived from an independent, drug-naive PD cohort, and prospective data from the general population. Our key results are (1) longitudinal trajectory of metabolites associated with the interconversion of methionine and cysteine via cystathionine differed between PD patients and controls; (2) dopaminergic medication showed strong lipidomic signatures; (3) taurine-conjugated bile acids correlated with the severity of motor symptoms, while low levels of sulfated taurolithocholate were associated with PD incidence in the general population; and (4) computational modeling predicted changes in sulfur metabolism, driven by A.

View Article and Find Full Text PDF

Human prolyl hydroxylases are involved in the modification of transcription factors, procollagen, and ribosomal proteins, and are current medicinal chemistry targets. To date, there are few reports on inhibitors selective for the different types of prolyl hydroxylases. We report a structurally informed template-based strategy for the development of inhibitors selective for the human ribosomal prolyl hydroxylase OGFOD1.

View Article and Find Full Text PDF
Article Synopsis
  • * The study compares four PHD inhibitors in clinical trials, detailing their mechanisms, how effectively they inhibit the enzymes, and their selectivity for different enzyme subfamilies.
  • * Crystallographic and NMR studies reveal variations in how these inhibitors bind to the enzymes, while cell studies show they similarly upregulate HIF target genes but differ in how quickly they act and the degree to which they inhibit hydroxylation of specific regions of the HIF protein.
View Article and Find Full Text PDF

The human retrovirus HTLV-1 causes a hematological malignancy or neuroinflammatory disease in ∼10% of infected individuals. HTLV-1 primarily infects CD4 T lymphocytes and persists as a provirus integrated in their genome. HTLV-1 appears transcriptionally latent in freshly isolated cells; however, the chronically active anti-HTLV-1 cytotoxic T cell response observed in infected individuals indicates frequent proviral expression in vivo.

View Article and Find Full Text PDF

Complement C1q is part of the C1 macromolecular complex that mediates the classical complement activation pathway: a major arm of innate immune defense. C1q is composed of A, B, and C chains that require post-translational prolyl 4-hydroxylation of their N-terminal collagen-like domain to enable the formation of the functional triple helical multimers. The prolyl 4-hydroxylase(s) that hydroxylate C1q have not previously been identified.

View Article and Find Full Text PDF
Article Synopsis
  • - Dysfunction or death from intracerebral hemorrhage (ICH) can result from oxidative stress caused by free iron, which leads to neuronal damage.
  • - Iron chelators, like the hydroxyquinoline inhibitor adaptaquin, can help protect neurons and improve recovery after ICH by targeting iron-dependent enzymes called HIF-PHDs.
  • - Adaptaquin's protective effects against neuronal death appear to involve inhibiting the pro-death factor ATF4, rather than activating survival pathways, showing potential for better outcomes in ICH treatment.
View Article and Find Full Text PDF

N-Methylation of lysine and arginine residues has emerged as a major mechanism of transcriptional regulation in eukaryotes. In humans, N(ε)-methyllysine residue demethylation is catalysed by two distinct subfamilies of demethylases (KDMs), the flavin-dependent KDM1 subfamily and the 2-oxoglutarate- (2OG) dependent JmjC subfamily, which both employ oxidative mechanisms. Modulation of histone methylation status is proposed to be important in epigenetic regulation and has substantial medicinal potential for the treatment of diseases including cancer and genetic disorders.

View Article and Find Full Text PDF

A naphthoquinone inhibitor of human arylamine N-acetyltransferase 1 (hNAT1), a potential cancer biomarker and therapeutic target, has been reported which undergoes a distinctive concomitant color change from red to blue upon binding to the enzyme. Here we describe the use of in silico modeling alongside structure-activity relationship studies to advance the hit compound towards a potential probe to quantify hNAT1 levels in tissues. Derivatives with both a fifty-fold higher potency against hNAT1 and a two-fold greater absorption coefficient compared to the initial hit have been synthesized; these compounds retain specificity for hNAT1 and its murine homologue mNat2 over the isoenzyme hNAT2.

View Article and Find Full Text PDF

Human arylamine N-acetyltransferase 1 (hNAT1) has become an attractive potential biomarker for estrogen-receptor-positive breast cancers. We describe here the mechanism of action of a selective non-covalent colorimetric biosensor for the recognition of hNAT1 and its murine homologue, mNat2, over their respective isoenzymes, leading to new opportunities in diagnosis. On interaction with the enzyme, the naphthoquinone probe undergoes an instantaneous and striking visible color change from red to blue.

View Article and Find Full Text PDF
Article Synopsis
  • 2-Oxoglutarate (2OG) and iron-dependent oxygenases are important targets for treating human diseases, and this study evaluates two new inhibitors, IOX1 and 4C8HQ, against common inhibitors like NOG and 2,4-PDCA.
  • The findings show that IOX1 effectively inhibits a wide range of 2OG oxygenases, including those related to histone and nucleic acid demethylation, and works in both cytosolic and nuclear environments without needing chemical modifications.
  • Additionally, unique crystallographic studies reveal that IOX1 can cause significant movement of an active site metal in the oxygenases, which is an unusual phenomenon not seen with 4C8HQ.
View Article and Find Full Text PDF